CSPC Pharmaceutical Group (HKG:1093) has obtained approval from China's National Medical Products Administration for the clinical trial of SYS6026, a therapeutic bivalent messenger RNA (mRNA) vaccine, a Tuesday bourse filing said.
The vaccine is used against relevant precancerous lesions caused by the human papillomavirus (HPV) type 16 or 18, according to the pharmaceutical firm.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments